{"filing":{"accession_number":"0001193125-26-342371","cik":"0001770121","ticker":"SANA","company_name":"Sana Biotechnology, Inc.","form":"8-K","filing_date":"2026-08-10","report_date":"2026-08-10","primary_document":"sana-20260810.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1770121/000119312526342371/sana-20260810.htm"},"events":[{"id":26564,"run_id":24146,"accession_number":"0001193125-26-342371","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a clear earnings release disclosing Sana Biotechnology's financial results for Q2 2026 (quarter ended June 30, 2026), filed under Item 2.02 Results of Operations and Financial Condition. The press release (Exhibit 99.1) reports GAAP and non-GAAP financial metrics including cash position ($160.5M), R\u0026D expenses ($30.7M for Q2), net loss ($63.6M for Q2), and operating cash burn, along with business highlights on clinical program progress. This is a standard quarterly earnings disclosure material to investors assessing the company's financial condition and operational progress.","company_name":"Sana Biotechnology, Inc.","ticker":"SANA","filing_date":"2026-08-10","form":"8-K","submitted_at":null,"items":[{"id":27730,"accession_number":"0001193125-26-342371","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release disclosing Sana Biotechnology's financial results for Q2 2026 (quarter ended June 30, 2026), filed under Item 2.02 Results of Operations and Financial Condition. The press release (Exhibit 99.1) reports GAAP and non-GAAP financial metrics including cash position ($160.5M), R\u0026D expenses ($30.7M for Q2), net loss ($63.6M for Q2), and operating cash burn, along with business highlights on clinical program progress. This is a standard quarterly earnings disclosure material to investors assessing the company's financial condition and operational progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:15:26.719104+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27730,"accession_number":"0001193125-26-342371","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release disclosing Sana Biotechnology's financial results for Q2 2026 (quarter ended June 30, 2026), filed under Item 2.02 Results of Operations and Financial Condition. The press release (Exhibit 99.1) reports GAAP and non-GAAP financial metrics including cash position ($160.5M), R\u0026D expenses ($30.7M for Q2), net loss ($63.6M for Q2), and operating cash burn, along with business highlights on clinical program progress. This is a standard quarterly earnings disclosure material to investors assessing the company's financial condition and operational progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:15:26.719104+00:00","company_name":"Sana Biotechnology, Inc.","ticker":"SANA","filing_date":"2026-08-10"}]}